Diagnostic and Prognostic Value of ¹¹C-Methionine PET for Nonenhancing Gliomas

References

1. 1.↵
   2. Louis DN,
   3. Ohgaki H,
   4. Wiestler OD, et al

   . The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97–109 doi:10.1007/s00401-007-0243-4 pmid:17618441

   CrossRefPubMedWeb of Science
2. 2.↵
   2. Marumoto T,
   3. Saya H

   . Molecular biology of glioma. Adv Exp Med Biol 2012;746:2–11 doi:10.1007/978-1-4614-3146-6_1 pmid:22639155

   CrossRefPubMed
3. 3.↵
   2. Shapiro JR,
   3. Yung WK,
   4. Shapiro WR

   . Isolation, karyotype, and clonal growth of heterogeneous subpopulations of human malignant gliomas. Cancer Res 1981;41:2349–59 pmid:7016313

   Abstract/FREE Full Text
4. 4.↵
   2. Lasocki A,
   3. Tsui A,
   4. Tacey MA, et al

   . MRI grading versus histology: predicting survival of World Health Organization grade II-IV astrocytomas. AJNR Am J Neuroradiol 2015;36:77–83 doi:10.3174/ajnr.A4077 pmid:25104288

   Abstract/FREE Full Text
5. 5.↵
   2. Chen W,
   3. Silverman DH

   . Advances in evaluation of primary brain tumors. Semin Nucl Med 2008;38:240–50 doi:10.1053/j.semnuclmed.2008.02.005 pmid:18514080

   CrossRefPubMed
6. 6.↵
   2. Batra A,
   3. Tripathi RP,
   4. Singh AK

   . Perfusion magnetic resonance imaging and magnetic resonance spectroscopy of cerebral gliomas showing imperceptible contrast enhancement on conventional magnetic resonance imaging. Australas Radiol 2004;48:324–32 doi:10.1111/j.0004-8461.2004.01315.x pmid:15344981

   CrossRefPubMed
7. 7.↵
   2. Fan GG,
   3. Deng QL,
   4. Wu ZH, et al

   . Usefulness of diffusion/perfusion-weighted MRI in patients with non-enhancing supratentorial brain gliomas: a valuable tool to predict tumour grading? Br J Radiol 2006;79:652–58 doi:10.1259/bjr/25349497 pmid:16641420

   Abstract/FREE Full Text
8. 8.↵
   2. Barker FG 2nd.,
   3. Chang SM,
   4. Valk PE, et al

   . 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma. Cancer 1997;79:115–26 pmid:8988735

   CrossRefPubMedWeb of Science
9. 9.↵
   2. Liu X,
   3. Tian W,
   4. Kolar B, et al

   . MR diffusion tensor and perfusion-weighted imaging in preoperative grading of supratentorial nonenhancing gliomas. Neuro Oncol 2011;13:447–55 doi:10.1093/neuonc/noq197 pmid:21297125

   Abstract/FREE Full Text
10. 10.↵
    2. Scott JN,
    3. Brasher PM,
    4. Sevick RJ, et al

    . How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology 2002;59:947–49 doi:10.1212/WNL.59.6.947 pmid:12297589

    Abstract/FREE Full Text
11. 11.↵
    2. Ginsberg LE,
    3. Fuller GN,
    4. Hashmi M, et al

    . The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: histopathological evaluation of a series. Surg Neurol 1998;49:436–40 doi:10.1016/S0090-3019(97)00360-1 pmid:9537664

    CrossRefPubMedWeb of Science
12. 12.↵
    2. Maia AC Jr.,
    3. Malheiros SM,
    4. da Rocha AJ, et al

    . MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas. AJNR Am J Neuroradiol 2005;26:777–83 pmid:15814920

    Abstract/FREE Full Text
13. 13.↵
    2. Berger G,
    3. Maziere M,
    4. Knipper R, et al

    . Automated synthesis of 11C-labelled radiopharmaceuticals: imipramine, chlorpromazine, nicotine and methionine. Int J Appl Radiat Isot 1979;30:393–99 doi:10.1016/0020-708X(79)90049-8 pmid:478664

    CrossRefPubMed
14. 14.↵
    2. Yoshiura T,
    3. Mihara F,
    4. Tanaka A, et al

    . High b value diffusion-weighted imaging is more sensitive to white matter degeneration in Alzheimer's disease. Neuroimage 2003;20:413–19 doi:10.1016/S1053-8119(03)00342-2 pmid:14527601

    CrossRefPubMedWeb of Science
15. 15.↵
    2. Di Chiro G,
    3. DeLaPaz RL,
    4. Brooks RA, et al

    . Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography. Neurology 1982;32:1323–29 doi:10.1212/WNL.32.12.1323 pmid:6983044

    Abstract/FREE Full Text
16. 16.↵
    2. Ishikawa M,
    3. Kikuchi H,
    4. Miyatake S, et al

    . Glucose consumption in recurrent gliomas. Neurosurgery 1993;33:28–33 doi:10.1227/00006123-199307000-00004 pmid:8355844

    CrossRefPubMedWeb of Science
17. 17.↵
    2. De Witte O,
    3. Levivier M,
    4. Violon P, et al

    . Prognostic value positron emission tomography with [18F]fluoro-2-deoxy-D-glucose in the low-grade glioma. Neurosurgery 1996;39:470–76; discussion 476–77 doi:10.1097/00006123-199609000-00007 pmid:8875476

    CrossRefPubMedWeb of Science
18. 18.↵
    2. Patronas NJ,
    3. Di Chiro G,
    4. Kufta C, et al

    . Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg 1985;62:816–22 doi:10.3171/jns.1985.62.6.0816 pmid:2987440

    CrossRefPubMedWeb of Science
19. 19.↵
    2. Alavi JB,
    3. Alavi A,
    4. Chawluk J, et al

    . Positron emission tomography in patients with glioma: a predictor of prognosis. Cancer 1988;62:1074–78 pmid:3261622

    CrossRefPubMedWeb of Science
20. 20.↵
    2. Goldman S,
    3. Levivier M,
    4. Pirotte B, et al

    . Regional glucose metabolism and histopathology of gliomas: a study based on positron emission tomography-guided stereotactic biopsy. Cancer 1996;78:1098–106 pmid:8780549

    CrossRefPubMedWeb of Science
21. 21.↵
    2. Pirotte B,
    3. Goldman S,
    4. Bidaut LM, et al

    . Use of positron emission tomography (PET) in stereotactic conditions for brain biopsy. Acta Neurochir (Wien) 1995;134:79–82 doi:10.1007/BF01428509 pmid:7668134

    CrossRefPubMed
22. 22.↵
    2. Ishizu K,
    3. Nishizawa S,
    4. Yonekura Y, et al

    . Effects of hyperglycemia on FDG uptake in human brain and glioma. J Nucl Med 1994;35:1104–09 pmid:8014665

    Abstract/FREE Full Text
23. 23.↵
    2. Padma MV,
    3. Said S,
    4. Jacobs M, et al

    . Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol 2003;64:227–37 doi:10.1023/A:1025665820001 pmid:14558598

    CrossRefPubMed
24. 24.↵
    2. Bergström M,
    3. Collins VP,
    4. Ehrin E, et al

    . Discrepancies in brain tumor extent as shown by computed tomography and positron emission tomography using [68Ga]EDTA, [11C]glucose, and [11C]methionine. J Comput Assist Tomogr 1983;7:1062–66 doi:10.1097/00004728-198312000-00022 pmid:6415134

    CrossRefPubMedWeb of Science
25. 25.↵
    2. Kato T,
    3. Shinoda J,
    4. Nakayama N, et al

    . Metabolic assessment of gliomas using 11C-methionine, [18F] fluorodeoxyglucose, and 11C-choline positron-emission tomography. AJNR Am J Neuroradiol 2008;29:1176–82 doi:10.3174/ajnr.A1008 pmid:18388218

    Abstract/FREE Full Text
26. 26.↵
    2. Borbély K,
    3. Nyáry I,
    4. Tóth M, et al

    . Optimization of semi-quantification in metabolic PET studies with 18F-fluorodeoxyglucose and 11C-methionine in the determination of malignancy of gliomas. J Neurol Sci 2006;246:85–94 doi:10.1016/j.jns.2006.02.015 pmid:16603193

    CrossRefPubMed
27. 27.↵
    2. Voges J,
    3. Herholz K,
    4. Hölzer T, et al

    . 11C-methionine and 18F-2-fluorodeoxyglucose positron emission tomography: a tool for diagnosis of cerebral glioma and monitoring after brachytherapy with 125I seeds. Stereotact Funct Neurosurg 1997;69(1–4 pt 2):129–35 pmid:9711745

    CrossRefPubMed
28. 28.↵
    2. Ogawa T,
    3. Inugami A,
    4. Hatazawa J, et al

    . Clinical positron emission tomography for brain tumors: comparison of fludeoxyglucose F 18 and L-methyl-11C-methionine. AJNR Am J Neuroradiol 1996;17:345–53 pmid:8938309

    Abstract
29. 29.↵
    2. Singhal T,
    3. Narayanan TK,
    4. Jain V, et al

    . 11C-L-methionine positron emission tomography in the clinical management of cerebral gliomas. Mol Imaging Biol 2008;10:1–18 doi:10.1007/s11307-007-0115-2 pmid:17957408

    CrossRefPubMed
30. 30.↵
    2. Utriainen M,
    3. Metsähonkala L,
    4. Salmi TT, et al

    . Metabolic characterization of childhood brain tumors: comparison of 18F-fluorodeoxyglucose and 11C-methionine positron emission tomography. Cancer 2002;95:1376–86 doi:10.1002/cncr.10798 pmid:12216107

    CrossRefPubMedWeb of Science
31. 31.↵
    2. Derlon JM,
    3. Chapon F,
    4. Noël MH, et al

    . Non-invasive grading of oligodendrogliomas: correlation between in vivo metabolic pattern and histopathology. Eur J Nucl Med 2000;27:778–87 doi:10.1007/s002590000260 pmid:10952489

    CrossRefPubMedWeb of Science
32. 32.↵
    2. Kaschten B,
    3. Stevenaert A,
    4. Sadzot B, et al

    . Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 1998;39:778–85 pmid:9591574

    Abstract/FREE Full Text
33. 33.↵
    2. Singhal T,
    3. Narayanan TK,
    4. Jacobs MP, et al

    . 11C-methionine PET for grading and prognostication in gliomas: a comparison study with 18F-FDG PET and contrast enhancement on MRI. J Nucl Med 2012;53:1709–15 doi:10.2967/jnumed.111.102533 pmid:23055534

    Abstract/FREE Full Text
34. 34.↵
    2. Bergström M,
    3. Lundqvist H,
    4. Ericson K, et al

    . Comparison of the accumulation kinetics of L-(methyl-11C)-methionine and D-(methyl-11C)-methionine in brain tumors studied with positron emission tomography. Acta Radiol 1987;28:225–29 doi:10.1177/028418518702800301 pmid:2958026

    Abstract/FREE Full Text
35. 35.↵
    2. Roelcke U,
    3. Radü E,
    4. Ametamey S, et al

    . Association of rubidium and C-methionine uptake in brain tumors measured by positron emission tomography. J Neurooncol 1996;27:163–71 pmid:8699239

    PubMed
36. 36.↵
    2. Jager PL,
    3. Vaalburg W,
    4. Pruim J, et al

    . Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 2001;42:432–45 pmid:11337520

    Abstract/FREE Full Text
37. 37.↵
    2. Kinoshita M,
    3. Hashimoto N,
    4. Goto T, et al

    . Fractional anisotropy and tumor cell density of the tumor core show positive correlation in diffusion tensor magnetic resonance imaging of malignant brain tumors. Neuroimage 2008;43:29–35 doi:10.1016/j.neuroimage.2008.06.041 pmid:18672074

    CrossRefPubMedWeb of Science
38. 38.↵
    2. LaViolette PS,
    3. Mickevicius NJ,
    4. Cochran EJ, et al

    . Precise ex vivo histological validation of heightened cellularity and diffusion-restricted necrosis in regions of dark apparent diffusion coefficient in 7 cases of high-grade glioma. Neuro Oncol 2014;16:1599–606 doi:10.1093/neuonc/nou142 pmid:25059209

    Abstract/FREE Full Text
39. 39.↵
    2. van den Bent MJ,
    3. Afra D,
    4. de Witte O, et al

    . Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366:985–90 doi:10.1016/S0140-6736(05)67070-5 pmid:16168780

    CrossRefPubMedWeb of Science
40. 40.↵
    2. Cairncross G,
    3. Berkey B,
    4. Shaw E, et al

    Intergroup Radiation Therapy Oncology Group Trial 9402, Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 2006;24:2707–14 doi:10.1200/JCO.2005.04.3414 pmid:16782910

    Abstract/FREE Full Text
41. 41.↵
    2. Gilbert MR,
    3. Friedman HS,
    4. Kuttesch JF, et al

    . A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. Neuro Oncol 2002;4:261–67 doi:10.1093/neuonc/4.4.261 pmid:12356356

    Abstract/FREE Full Text
42. 42.↵
    2. Shibui S,
    3. Narita Y,
    4. Mizusawa J, et al

    . Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305). Cancer Chemother Pharmacol 2013;71:511–21 doi:10.1007/s00280-012-2041-5 pmid:23228988

    CrossRefPubMed
43. 43.↵
    2. Brandes AA,
    3. Nicolardi L,
    4. Tosoni A, et al

    . Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma. Neuro Oncol 2006;8:253–60 doi:10.1215/15228517-2006-005 pmid:16723632

    Abstract/FREE Full Text
44. 44.↵
    2. van den Bent MJ,
    3. Carpentier AF,
    4. Brandes AA, et al

    . Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 2006;24:2715–22 doi:10.1200/JCO.2005.04.6078 pmid:16782911

    Abstract/FREE Full Text
45. 45.↵
    2. Wick W,
    3. Hartmann C,
    4. Engel C, et al

    . NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009;27:5874–80 doi:10.1200/JCO.2009.23.6497 pmid:19901110

    Abstract/FREE Full Text
46. 46.↵
    2. Cairncross G,
    3. Wang M,
    4. Shaw E, et al

    . Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 2013;31:337–43 doi:10.1200/JCO.2012.43.2674 pmid:23071247

    Abstract/FREE Full Text
47. 47.↵
    2. Suzuki H,
    3. Aoki K,
    4. Chiba K, et al

    . Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet 2015;47:458–68 doi:10.1038/ng.3273 pmid:25848751

    CrossRefPubMed